Artiva Biotherapeutics Inc
ARTV3.060USD
+0.230+8.13%
交易中 （美東）報價延遲15分鐘
74.55M總市值
虧損本益比TTM
關於 Artiva Biotherapeutics Inc 公司
Artiva Biotherapeutics, Inc. 是一家臨牀階段的生物技術公司，專注於爲患有毀滅性自身免疫性疾病和癌症的患者開發基於自然殺傷 (NK) 細胞的療法。該公司的候選產品源自供體細胞（同種異體）而非患者自身細胞（自體），並且是預先製造、冷凍儲存並隨時可運送到患者的治療地點。其主要候選產品 AlloNK 正在與 B 細胞靶向單克隆抗體 (mAb) 聯合用於治療自身免疫性疾病和癌症患者，例如 LN、RA、PV、ANCA 相關性血管炎亞型 GPA/MPA、SLE 和 B-NHL。 AlloNK 是一種非轉基因、冷凍保存的 NK 細胞療法，目前正在進行一項針對 III 類或 IV 類狼瘡性腎炎 (LN) 的 I/Ib 期試驗，以及一項針對多種自身免疫適應症的研究者發起的籃子試驗 (IIT) 中對與 B 細胞靶向 mAb 聯合進行評估。
公司簡介
公司代碼ARTV
公司名稱Artiva Biotherapeutics Inc
上市日期Jul 19, 2024
CEODr. Fred Aslan, M.D.
員工數量89
證券類型Ordinary Share
年結日Jul 19
公司地址5505 Morehouse Drive
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編92121
電話18582674467
網址https://www.artivabio.com/
公司代碼ARTV
上市日期Jul 19, 2024
CEODr. Fred Aslan, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
43.35K
+333.50%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
3.75K
-96.59%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Dr. Alison Moore, Ph.D.
Dr. Alison Moore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Dr. Brian Daniels, M.D.
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
43.35K
+333.50%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
3.75K
-96.59%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
收入明細
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q1
FY2022
暫無數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 7月19日 週六
更新時間: 7月19日 週六
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
40.44%
GC Biopharma Corp
18.75%
5AM Ventures
9.66%
VR Adviser, LLC
6.61%
VenBio Partners LLC
4.92%
Other
19.62%
持股股東
持股股東
佔比
RA Capital Management, LP
40.44%
GC Biopharma Corp
18.75%
5AM Ventures
9.66%
VR Adviser, LLC
6.61%
VenBio Partners LLC
4.92%
Other
19.62%
股東類型
持股股東
佔比
Venture Capital
58.50%
Corporation
18.75%
Investment Advisor
13.06%
Investment Advisor/Hedge Fund
6.64%
Private Equity
4.92%
Hedge Fund
2.37%
Individual Investor
1.24%
Research Firm
0.43%
Sovereign Wealth Fund
0.12%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
102
25.86M
106.14%
+3.25M
2025Q1
101
26.68M
109.52%
+4.03M
2024Q4
89
26.90M
110.75%
+5.25M
2024Q3
74
26.42M
108.79%
+10.37M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
9.85M
40.44%
--
--
Mar 31, 2025
GC Biopharma Corp
4.57M
18.75%
+4.57M
--
Jul 22, 2024
5AM Ventures
2.35M
9.66%
--
--
Mar 31, 2025
VR Adviser, LLC
1.61M
6.61%
--
--
Mar 31, 2025
VenBio Partners LLC
1.20M
4.92%
-321.00K
-21.12%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.16M
4.74%
+189.32K
+19.60%
Mar 31, 2025
Capital World Investors
866.62K
3.56%
-48.76K
-5.33%
Mar 31, 2025
The Vanguard Group, Inc.
858.21K
3.52%
-8.71K
-1.00%
Mar 31, 2025
Franklin Advisers, Inc.
520.33K
2.14%
+26.00
+0.00%
Mar 31, 2025
Geode Capital Management, L.L.C.
410.46K
1.68%
+94.70K
+29.99%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Biotechnology ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
查看更多
iShares Biotechnology ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
ProShares Hedge Replication ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ProShares UltraPro Russell2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
